Biotech entity
All 1 tracked stories fall under one category: fda-approval. Of the tracked stories, 1 of 1 also mention Bitopertin, the most common co-covered peer. The tracked stories average 2 original sources each. APOLLO appears in 1 tracked Biotech story from February 23, 2026.
Last mentioned: Mar 14, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
All 1 tracked stories fall under one category: fda-approval. Of the tracked stories, 1 of 1 also mention Bitopertin, the most common co-covered peer. The tracked stories average 2 original sources each. APOLLO appears in 1 tracked Biotech story from February 23, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 6 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering APOLLO. Shared-story counts are live from our verified record — not editorial picks.
APOLLO Trial Data
Expected top-line results from the Phase 2/3 APOLLO trial in Q4 2026.
Regulatory Pivot
Disc Medicine announces shift to traditional approval pathway.
FDA CRL Issued
FDA rejects accelerated approval pathway for bitopertin in EPP.
Disc Medicine has shifted its regulatory strategy for bitopertin in erythropoietic protoporphyria (EPP) following an FDA Complete Response Letter regarding its accelerated approval bid. The company will now focus on a traditional approval route, with pivotal Phase 2/3 APOLLO trial data expected in Q4 2026.
APOLLO is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
